Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $6.00.
A number of brokerages recently weighed in on PIRS. ValuEngine raised shares of Pieris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Pieris Pharmaceuticals in a research report on Thursday, August 1st. William Blair reissued a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Friday, August 16th. Zacks Investment Research raised shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 17th. Finally, Robert W. Baird cut shares of Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target for the company. in a research report on Tuesday, July 30th.
In other news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $4.50, for a total value of $225,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.59% of the stock is currently owned by corporate insiders.
PIRS traded up $0.48 on Friday, reaching $5.76. The company had a trading volume of 2,006,060 shares, compared to its average volume of 550,393. Pieris Pharmaceuticals has a 1 year low of $2.39 and a 1 year high of $6.04. The stock has a market capitalization of $260.79 million, a PE ratio of -11.52 and a beta of 1.31. The stock has a 50-day moving average price of $4.97 and a 200-day moving average price of $4.11.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Friday, August 9th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). Pieris Pharmaceuticals had a negative net margin of 147.19% and a negative return on equity of 114.25%. The company had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $7.32 million. On average, equities analysts expect that Pieris Pharmaceuticals will post -0.86 earnings per share for the current year.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: How does a margin account work?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.